Introduction
Quinestrol (Estrovis) which is the 3-cyclopentyl ether of ethinyl oestradiol,has been the subject of extensive clinical evaluation since it was first introduced for the inhibition and suppression of lactation in 1967. It has been compared with the conventional oestrogens, ethinyl oestradiol and stilboestrol (Kuku 1968 , Watson 1969 , Brett, Douglas and Walker 1971 , Plater 1971 , with the only other fat stored oestrogen on the market, chlorotrianisene (King 1972), with no oestrogen therapy (McGlone 1969 , Hodge and Maiti 1971 ,Cruttenden 1971 and fluid loading (Roberts 1970) .
In the trials mentioned where quinestrol was compared with placebo forms of therapy it was found to be significantly superior to inert preparations in inhibiting lactation. These findings contrast with the views of MacDonald and O'Driscoll who suggest that exhibition of oestrogens is unnecessary in the inhibition or suppression of lactation (MacDonald and 0' Driscoll 1965).
If a decision is made to use an oestrogen to inhibit or suppress lactation it would seem reasonable to keep the dosage as low as possible (Miller 1969) . Quinestrol (as a 4 mg single tablet for inhibition of lactation and 1 or 2 tablets for suppression of established lactation) would appear to be a simple and effective oestrogen which would meet this requirement.
As quinestrol had not previously been evaluated in a Service Establishment, it was decided to carry out a comparison of quinestrol with placebo under double blind conditions in the Maternity Unit of the Military Hospital at Tidworth.
Method
Eighty patients who had elected not to breast feed were given either a single 4 mg quinestrol tablet or identical placebo under double blind conditions within six hours of delivery. Of the original 80 patients, 66 remained as in-patients for a minimum period of 
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five-days following delivery. The remaining 14 patients were observed for periods less than five days and were eliminated from the study. During the five-day in-patient stay daily records were kept of the condition of the breast with regard to consistency and lactation. The nature of the lochia, rate of involution and any side effects were also noted. In addition to this objective assessment by the clinician, the mother was questioned about breast comfort each day.
In order to determine the patient's progress following'discharge from hospital, a follow-up questionnaire was devised. Unfortunately, this phase of the trial coincided with a six-week suspension of postal services due to an industrial dispute, and it was decided to evaluate the trial results on the basis of the five-day in-patient stay.
Results
On completion of the trial it was found that .35 patients had been treated with quinestrol, whilst 31 patients had received the placebo tablet. The results of observer assessment are shown in Table I Side effects were very similar on the two trial preparations. In the group treated with quinestrol, headache was reported in three patients, nausea in two, diarrhoea in two and ankle oedema in one subject. In the patients receiving the placebo, headache was reported in three patients and nausea in two. The character of the lochia and rate of involution were within normal limits in all patients.
Discussion
In this limited trial quinestrol has thus been shown to be markedly superior to placebo in the inhibition oflactation as judged on five-day in-patient stay. It is unfortunate that circumstances prevented compilation of data on possible lactation ~ymptoms in the puerperium, but previous clinical trials have shown quinestrol to be highly effective in preventing' .rebound lactation".
